Current and emerging treatment options for nasopharyngeal carcinoma

References

• Al-SarrafMLeBlancMGiriPGChemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099J Clin Oncol199816131013179552031
   PubMed Web of Science ®Google Scholar
• LeeAWLauWHTungSYPreliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally- advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupJ Clin Oncol2005236966697516192584
   PubMed Web of Science ®Google Scholar
• WeeJTanEHTaiBCRandomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varietyJ Clin Oncol2005236730673816170180
   PubMed Web of Science ®Google Scholar
• KwongDLShamJSAuGKConcurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial studyJ Clin Oncol2004222643265315226332
   PubMed Web of Science ®Google Scholar
• LinJCJanJSHsuCYLiangWMJiangRSWangWYPhase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survivalJ Clin Oncol20032163163712586799
   PubMed Web of Science ®Google Scholar
• ChanATNasopharyngeal carcinomaAnn Oncol200221Suppl 7vii30831220943634
   PubMed Web of Science ®Google Scholar
• WangWYTwuCWChenHHPlasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinomaClin Cancer Res2010161016102420103659
   PubMed Web of Science ®Google Scholar
• Al-SarrafMPajakTFMarcialVAConcurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG StudyCancer1987592592653802013
   PubMed Web of Science ®Google Scholar
• Al-SarrafMPajakTFCooperJSMohiuddinMHerskovicAAgerPJChemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group studyJ Clin Oncol19908134213512199621
   PubMed Web of Science ®Google Scholar
• CooperJSLeeHTorreyMHochsterHImproved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experienceInt J Radiat Oncol Biol Phys20004786186610863053
   PubMed Web of Science ®Google Scholar
• ChanATTeoPMNganRKConcurrent chemotherapy- radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trialJ Clin Oncol2002202038204411956263
   PubMed Web of Science ®Google Scholar
• ChanATLeungSFNganRKOverall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinomaJ Natl Cancer Inst20059753653915812080
   PubMed Web of Science ®Google Scholar
• LeeAWTungSYChanATPreliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20066614215116904519
   PubMed Web of Science ®Google Scholar
• ChenYLiuMZLiangSBPreliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of ChinaInt J Radiat Oncol Biol Phys2008711356136418472356
   PubMed Web of Science ®Google Scholar
• ChanATTeoPMLeungTWA prospective randomized study of chemotherapy adjunctive to def initive radiotherapy in advanced nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys1995335695777558945
   PubMed Web of Science ®Google Scholar
• Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trialInt J Radiat Oncol Biol Phys1996354634698655368
   PubMed Web of Science ®Google Scholar
• MaJMaiHQHongMHResults of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinomaJ Clin Oncol2001191350135711230478
   PubMed Web of Science ®Google Scholar
• ChuaDTShamJSChoyDPreliminary report of the Asian- Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study GroupCancer199883227022839840526
   PubMed Web of Science ®Google Scholar
• ChuaDTMaJShamJSLong-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trialsJ Clin Oncol2005231118112415657403
   PubMed Web of Science ®Google Scholar
• HareyamaMSakataKShiratoHA prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinomaCancer2002942217222312001120
   PubMed Web of Science ®Google Scholar
• HuiEPMaBBLeungSFRandomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinomaJ Clin Oncol20092724224919064973
   PubMed Web of Science ®Google Scholar
• FountzilasGCiuleanuEBobosMInduction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationAnn Oncol20122342743521525406
   PubMed Web of Science ®Google Scholar
• RossiAMolinariRBoracchiPAdjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized studyJ Clin Oncol19886140114103047335
   PubMed Web of Science ®Google Scholar
• ChiKHChangYCGuoWYA phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patientsInt J Radiat Oncol Biol Phys2002521238124411955734
   PubMed Web of Science ®Google Scholar
• HuWDingWYangHWeekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinomaRadiother Oncol20099348849119679366
   PubMed Web of Science ®Google Scholar
• ChenLHuCSChenXZConcurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLancet Oncol20121316317122154591
   PubMed Web of Science ®Google Scholar
• ZhangLZhaoCGhimireBThe role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trialsBMC Cancer20101055820950416
   PubMed Web of Science ®Google Scholar
• BaujatBAudryHBourhisJChemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patientsInt J Radiat Oncol Biol Phys200664475616377415
   PubMed Web of Science ®Google Scholar
• LangendijkJALeemansCRButerJBerkhofJSlotmanBJThe additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literatureJ Clin Oncol2004224604461215542811
   PubMed Web of Science ®Google Scholar
• HuncharekMKupelnickBCombined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trialsAm J Clin Oncol20022521922312040275
   PubMed Web of Science ®Google Scholar
• BaujatBAudryHBourhisJMAC-NPC Collaborative GroupChemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinomaCochrane Database Syst Rev20064CD00432917054200
   PubMed Web of Science ®Google Scholar
• XiaPFuKKWongGWAkazawaCVerheyLJComparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20004832933710974445
   PubMed Web of Science ®Google Scholar
• KamMKChauRMSuenJChoiPHTeoPMIntensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalationInt J Radiat Oncol Biol Phys20035614515712694833
   PubMed Web of Science ®Google Scholar
• HuntMAZelefskyMJWoldenSTreatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancerInt J Radiat Oncol Biol Phys20014962363211172942
   PubMed Web of Science ®Google Scholar
• WuVWKwongDLShamJSTarget dose conformity in 3- dimensional conformal radiotherapy and intensity modulated radiotherapyRadiother Oncol20047120120615110454
   PubMed Web of Science ®Google Scholar
• WoldenSLChenWCPfisterDGKrausDHBerrySLZelefskyMJIntensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experienceInt J Radiat Oncol Biol Phys200664576215936155
   PubMed Web of Science ®Google Scholar
• LeeNXiaPQuiveyJMIntensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experienceInt J Radiat Oncol Biol Phys200253122212007936
   PubMed Web of Science ®Google Scholar
• PowEHKwongDLMcMillanASXerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trialInt J Radiat Oncol Biol Phys20066698199117145528
   PubMed Web of Science ®Google Scholar
• KwongDLPowEHShamJSIntensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary functionCancer20041011584159315378492
   PubMed Web of Science ®Google Scholar
• LeeNHarrisJGardenASIntensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225J Clin Oncol2009273684369019564532
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med200635456757816467544
   PubMed Web of Science ®Google Scholar
• ChanATHsuMMGohBCMulticenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaJ Clin Oncol2005233568357615809453
   PubMed Web of Science ®Google Scholar
• MaBBKamMKLeungSFA phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinomaAnn Oncol2012231287129221948811
   PubMed Web of Science ®Google Scholar
• RazakARSiuLLLe TourneauCMolecular targeted therapies in all histologies of head and neck cancers: an updateCurr Opin Oncol20102221222020173639
   PubMed Web of Science ®Google Scholar
• KrishnaSMJamesSBalaramPExpression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV statusVirus Res2006115859016139912
   PubMed Web of Science ®Google Scholar
• XiaoXWuJZhuXInduction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinaseInt J Cancer20071212095210417631646
   PubMed Web of Science ®Google Scholar
• LeeNYZhangQPfisterDGAddition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trialLancet Oncol20121317218022178121
   PubMed Web of Science ®Google Scholar
• WidesottLPierelliAFiorinoCIntensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluationInt J Radiat Oncol Biol Phys20087258959618793962
   PubMed Web of Science ®Google Scholar
• BrownAPUrieMMChisinRSuitHDProton therapy for carcinoma of the nasopharynx: a study in comparative treatment planningInt J Radiat Oncol Biol Phys198916160716142542199
   PubMed Web of Science ®Google Scholar
• Taheri-KadkhodaZBjork-ErikssonTNillSIntensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protonsRadiat Oncol20083418218078
   PubMed Web of Science ®Google Scholar
• van de WaterTABijlHPSchilstraCPijls-JohannesmaMLangendijkJAThe potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literatureOncologist20111636637721349950
   PubMed Web of Science ®Google Scholar
• BhideSADaviesMBurkeKWeekly volume and dosimetric changes during chemoradiotherapy with intensity- modulated radiation therapy for head and neck cancer: a prospective observational studyInt J Radiat Oncol Biol Phys2010761360136820338474
   PubMed Web of Science ®Google Scholar
• ZhaoLWanQZhouYDengXXieCWuSThe role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinomaRadiother Oncol201198232721040992
   PubMed Web of Science ®Google Scholar
• HenleWHenleGHoHCAntibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groupsJ Natl Cancer Inst19704422523111515035
   PubMedGoogle Scholar
• XuJWanXBHuangXFSerologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinomaJ Clin Oncol2010285202520921060035
   PubMed Web of Science ®Google Scholar
• FanHNichollsJChuaDLaboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virusInt J Cancer20041121036104115386346
   PubMed Web of Science ®Google Scholar
• ShaoJYLiYHGaoHYComparison of plasma Epstein- Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinomaCancer20041001162117015022282
   PubMed Web of Science ®Google Scholar
• NeelHB3rdTaylorWFEpstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinomaArch Otolaryngol Head Neck Surg1990116128712902173618
   PubMedGoogle Scholar
• YipTTNganRKLauWHA possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinomaCancer199474241424247922994
   PubMed Web of Science ®Google Scholar
• TwuCWWangWYLiangWMComparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20076713013716979842
   PubMed Web of Science ®Google Scholar
• de-VathaireFSancho-GarnierHde-TheHPrognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up studyInt J Cancer1988421761812841245
   PubMed Web of Science ®Google Scholar
• LoYMChanATChanLYMolecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNACancer Res2000606878688111156384
   PubMed Web of Science ®Google Scholar
• LoYMLeungSFChanLYPlasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical stagingAnn N Y Acad Sci20009069910110818603
   PubMed Web of Science ®Google Scholar
• MaBBKingALoYMRelationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20066671472017011447
   PubMed Web of Science ®Google Scholar
• LeungSFChanATZeeBPretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated typeCancer20039828829112872347
   PubMed Web of Science ®Google Scholar
• LeungSFZeeBMaBBPlasma Epstein-Bar r viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinomaJ Clin Oncol2006245414541817135642
   PubMed Web of Science ®Google Scholar
• LinJCWangWYChenKYQuantification of plasma Epstein- Barr virus DNA in patients with advanced nasopharyngeal carcinomaN Engl J Med20043502461247015190138
   PubMed Web of Science ®Google Scholar
• ChanATLoYMZeeBPlasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinomaJ Natl Cancer Inst2002941614161912419787
   PubMed Web of Science ®Google Scholar
• WangWYTwuCWLinWYPlasma Epstein-Barr virus DNA screening followed by (1)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinomaCancer20111174452445921437892
   PubMed Web of Science ®Google Scholar
• PanJJZhangSWChenCBEffect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinomaJ Clin Oncol20092779980419103729
   PubMed Web of Science ®Google Scholar
• ZhangLZhaoCPengPJPhase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary resultsJ Clin Oncol2005238461846816230677
   PubMed Web of Science ®Google Scholar
• KamMKTeoPMChauRMTreatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experienceInt J Radiat Oncol Biol Phys2004601440145015590175
   PubMed Web of Science ®Google Scholar
• ThamIWHeeSWYeoRMTreatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the National Cancer Centre Singapore experienceInt J Radiat Oncol Biol Phys2009751481148619386431
   PubMed Web of Science ®Google Scholar
• LinSPanJHanLZhangXLiaoXLuJJNasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective seriesInt J Radiat Oncol Biol Phys2009751071107819362784
   PubMed Web of Science ®Google Scholar
• WongFCNgAWLeeVHWhole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20107613814519646824
   PubMed Web of Science ®Google Scholar
• NgWTLeeMCHungWMClinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys20107942042820452132
   PubMed Web of Science ®Google Scholar
• XiaoWWHuangSMHanFLocal control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 studyCancer20111171874188321509764
   PubMed Web of Science ®Google Scholar
• LaiSZLiWFChenLHow does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?Int J Radiat Oncol Biol Phys20118066166820643517
   PubMed Web of Science ®Google Scholar